Revenue, 2025

USD 2.05 Billion

Forecast, 2035

USD 3.65 Billion

CAGR, 2026-2035

5.94%

Report Coverage

Global

Latent Tuberculosis Infection Detection Market Trends for 2026

The global latent tuberculosis infection detection market size was estimated at USD 2.05 billion in 2025 and is predicted to increase from USD 2.17 billion in 2026 to approximately USD 3.65 billion by 2035, expanding at a CAGR of 5.94% from 2026 to 2035.

The latent tuberculosis infection detection market is growing due to this treatment allowing preventive treatment that stops the infection from emerging into active, and transmissible TB disease.

Key Takeaways

• The latent tuberculosis infection detection market will likely exceed USD 2.17 billion by 2026.
• Valuation is projected to hit USD 3.65 billion by 2035.
• Estimated to grow at a CAGR of 5.94% starting from 2026 to 2035.
• Asia Pacific dominated the latent tuberculosis infection detection market by 44% in 2025.
• North America is expected to grow at the fastest CAGR in the market during the forecast period.
• By brand, the QFT-plus segment dominated the market by 70% in 2025 and is expected to grow fastest in the market during the forecast period.
• By test, the tuberculin skin test segment dominated the market by 60% in 2025.
• By test, the interferon gamma released assay segment is expected to grow fastest in the market during the forecast period.
• By application, the PLHIV segment dominated the market by 45% in 2025.
• By application, the household contacts with pulmonary TB segment are expected to grow fastest in the market during the forecast period.
• By end use, the diagnostic laboratories segment dominated the market by 50% in 2025.
• By end use, the hospital & clinics segment is expected to grow fastest in the market during the forecast period.

Market Overview: What is Latent Tuberculosis Infection Detection?

The latent tuberculosis infection detection market is growing, as treatment of LTBI is efficient in lowering the challenges of developing subsequent active TB disease. Advancements in present TB diagnostics are immediately required not only to enhance both sensitivity and specificity of Mtb infection detection but also to more precisely determine the challenges of progression or reactivation in the active disease. Treating patients with latent TB infection substantially lowers the risk that latent TB infection progresses to TB disease. The diagnosis of LTBI has always hinged on detecting immune responses to particular mycobacterial antigens, making the selection of these antigens significant for both identifying LTBI and emerging assays that differentiate among infection stages.

How is AI Transforming the Market?

Integration of AI-driven technology in latent tuberculosis infection detection drives latent tuberculosis infection detection market growth, as AI-based technology transforms TB control via enhanced ACF processes and triage, improving detection rates in high-burden areas. With increasing precision, AI-based technology can diagnose pleural diseases and differentiate active TB from TB infection. ML diagnoses TB, monitors treatment, and analyzes host biomarkers. This technology provides promising services to improve early detection, increase accuracy, and optimize treatment approaches, thereby potentially transforming TB management globally. AI-based algorithms analyze chest X-rays to identify abnormalities indicative of TB, like nodules, consolidations, or cavities. AI-based technology offers quantitative assessments of TB severity and progression from chest X-ray images, aiding clinicians in making well-informed decisions related to treatment approaches.

Future Outlook & Trends in the Latent Tuberculosis Infection Detection Market

Proteomic Advancements: 

The application of proteomics technology provides a new methodology for the diagnosis of LTBI. This strategy involves the detection and identification of proteins and their interactions that are closely related to the advancement of disease.

Predictive Diagnostics:

Predictive diagnostics for latent tuberculosis infection (LTBI) enhance traditional technology by identifying individuals at the highest risk of progressing to active disease, rather than detecting prior exposure.

Advancement of Biomarkers:

LTBI-specific biomarkers support the identification of patients who are at increasing risk of developing TB and prepare them to adhere to preventive therapy, thus lowering the worldwide burden of TB.

Key Indicators and Highlights 

Segmentation Analysis

By Brand Insights

Which Brand Segment Led the Market in 2025?

Explanation

• QFT-Plus (QuantiFERON-TB Gold Plus) (70%): Dominates due to its strong clinical validation, reliability, and established market presence in TB diagnostics.
• Others (30%): Does not dominate due to less recognition and fewer market shares compared to QFT-Plus.

The QFT-plus segment held the major share of the latent tuberculosis infection detection market 70% in 2025 and is expected to grow at the highest rate during 2026-2035, as QFT-plus showed high performance in the identification of TB infection in patients, irrespective of their age or lower CD4 counts. QuantiFERON-TB Plus enhances sensitivity for active TB and preserves high specificity in the unvaccinated controls. QFT-Plus was developed to improve Mtb test sensitivity and diagnostic precision compared with the preceding generation.

 By Test Insights

Which Test Segment Led the Market in 2025?

Explanation

• Tuberculin Skin Test (TST) (60%): Dominates as the traditional, widely used method with a lower cost and familiarity in clinical practice.
• Interferon Gamma Release Assay (IGRA) (40%): Gaining momentum due to higher accuracy and fewer false positives, becoming a more preferred alternative in many regions.

The tuberculin skin test segment was dominant in the latent tuberculosis infection detection market by 60% in 2025, as TST is a significant tool applied for active tuberculosis identification, with a moderate worldwide performance and accepted specificity and sensitivity. This test helps to find out if a patient is infected with TB germs. A tuberculin test is a skin test done to check the presence of TB-causing mycobacteria in a patient. It assesses the immune system's response to the antigen. This test supports early diagnosis and management of latent TB infection in high-risk patients who can develop active TB.

Interferon Gamma Released Assay:

Whereas the interferon gamma released assay segment is the fastest-growing in the market, a major advantage of IGRAs is the excellent performance of control by using the patient’s internal positive and negative control, lowering the rate of false-positive and false-negative outcomes of IGRA. IGRAs support lowering the number of patients who need preventive treatment, which is more significant in children.

By Application Insights

Why PLHIV Segment Led the Market in 2025?

Explanation

• PLHIV (45%): Dominates due to the high incidence of TB among people living with HIV, making it a key focus for testing and monitoring.
• Household Contacts with Pulmonary TB (35%): Gaining momentum as contacts of active TB cases are increasingly targeted for early detection and intervention.
• Others (20%): Not dominating as they represent a smaller, less prioritized segment in TB testing.

The PLHIV segment dominated the latent tuberculosis infection detection market by 45% in 2025, as management of latent tuberculosis infection lowers the challenges of active TB in HIV positive patients, particularly in those with a positive tuberculin skin test. The choice of regimen is based on factors like availability, expenses, adverse effects, adherence, and drug resistance. Patients living with HIV who have a positive test for LTBI benefit more from preventive treatment than those who have a negative LTBI test.

Household Contacts with Pulmonary TB

Whereas the household contacts with pulmonary TB segment is the fastest-growing in the market, as household contacts exposed to patients with pulmonary TB, in a diversity of settings, are at substantial risk of active TB and LTBI. Household contact screening of newly diagnosed TB index cases offers a modest yield of cases.  Contact examination links to efficient interventions like treatment for TB disease and TPT, supports to prevent transmission, and enhances TB treatment results for contacts.

By End Use Insights

Why the Diagnostic Laboratories Segment Led the Market in 2025?

Explanation

• Diagnostic Laboratories (50%): Dominates as they are the primary setting for TB testing, offering a range of diagnostic services.
• Hospitals/Clinics (35%): Gaining momentum due to the growing need for diagnostic services in clinical environments, though still secondary to laboratories.
• Academic & Research Institutions (15%): Does not dominate due to being a smaller market with a focus on research rather than mass diagnostics.

The diagnostic laboratories segment held the major revenue of the latent tuberculosis infection detection market by 50% in 2025, as in diagnostic laboratories, detection and treatment of latent tuberculosis (TB) infection (LTBI) is a key component of TB control efforts in low-incidence settings. The major benefits are agreeing on targeted preventive treatment for those infected, which significantly lowers their risk of developing active tuberculosis.

Hospital & Clinics:

Whereas the hospital & clinics segment is estimated to be the fastest-growing in the market, as hospitals and clinics adopt well-developed technology that treats patients with latent TB infection, significantly lowering the challenges that latent TB infection progresses to TB disease. Advanced tools have evolved, including the interferon-gamma release assays, which more precisely diagnose LTBI. Targeted testing and management of LTBI play a significant role in TB removal from patients.

Regional Insights

Asia Pacific: Rising Adoption of Advanced Technology

Asia Pacific dominated the latent tuberculosis infection detection market by 44% in 2025, as tuberculosis (TB) is the leading killer of the productive age group in developing countries. More than half of the cases in the world occur in the Asia-Pacific region. The increasing adoption of digital Chest X-rays (CXR) integrated with computer-aided detection (CAD) allows for fast, scalable, and precise screening. major population groups like migrants, miners, ethnic minorities, and indigenous populations, and other poor and remote communities, who have limited access to advanced healthcare and increasing burdens of TB, which contributes to the growth of the market.

India Market Trends

India remains to have the highest TB burden amid all countries, accounting for nearly a third of the incident TB cases and deaths worldwide. India has the strength to lead the world in advancing advanced TB diagnostics. Growing regulatory support, such as the Indian government's launch of the National Tuberculosis Elimination Program (NTEP), aims to eradicate TB.  The novel validated TB diagnostic tests provide major key advantages, including rapid outcomes and significantly lower expenses.

How did North America become the Fastest-Growing Region in the Market in 2025?

North America is estimated to be the fastest-growing region in the latent tuberculosis infection detection market because targeted testing for tuberculosis has a strategy to diagnose and manage latent TB infection in patients who are at risk for emerging TB disease.  Increasing focus on latent TB identification, regulatory funding initiatives, and hospital-based testing drives adoption. Strong public-private collaboration and a comprehensive reimbursement strategy drive the growth of the market.

U.S. Market Trends

In the U.S., the applications of digital diagnostic systems are becoming increasingly widespread, and teleradiology or telepathology are used for diagnosis. The quality of scanning, precise transmission of images, turnaround time, patient privacy, and availability of relevant previous images are paramount. Growing international travel and migration, associated with increasing TB cases in the immunocompromised populations, have intensified investigation efforts in the U.S.

Europe: Increasing Cases of TB

Europe is significantly growing in the latent tuberculosis infection detection market, because many countries in Europe have attained a low incidence of TB, with most novel TB diagnoses occurring in migrants from high-incidence countries. Around 60 000 cases of TB are reported yearly in the European Union/European Economic Area (EU/EEA), with maximum cases in countries in the area characterised by low incidence of the disease.

Supply Chain Analysis

R&D:

• Research and development (R&D) for latent tuberculosis infection detection includes shifting beyond traditional processes such as the Tuberculin Skin Test (TST) to more accurate, molecular, and biomarker-driven technologies.
• Key Players: F. Hoffmann-La Roche and Serum Institute of India Pvt. Ltd.

Manufacturing Processes:

• Manufacturing processes for latent tuberculosis infection detection focus on two main immunological strategies, such as the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs). 
• Key Players: bioMérieux and SD Biosensor

Patient Services:

• Patient services for latent tuberculosis infection detection mainly focus on identifying patients at risk of developing active tuberculosis and initiating preventative treatment to break the chain of detection.
• Key Players: Qiagen and Oxford Immunotec

Latest Updates of Key Players in the Latent Tuberculosis Infection Detection Market

SWOT Analysis

Strengths

• Diagnosis of LTBI is a significant component of TB prevention and control, supporting the detection and treatment of patients at an early stage, therefore limiting the spread of TB.
• Major screening services allow healthcare providers and public health programs to focus resources on high-risk populations such as recent contacts of active TB cases and immunocompromised individuals.

Weaknesses

• Treatment regimens for LTBI, such as isoniazid, cause adverse effects, specifically liver toxicity, which deters patient adherence and requires monitoring.
• Lengthy treatment time often results in poor patient compliance and treatment disappointment.

Opportunities

• Latest advancement in TB identification processes, including PET-CT, Xpert MTB/RIF, next-generation sequencing (NGS) and line probe assays, which validate exceptional sensitivity, accuracy, and versatility in various healthcare settings.
• Host blood‐resultant biomarkers grounded on tuberculosis parsimonious transcriptomic signatures showed strength to predict and diagnose immune reconstitution inflammatory syndrome based on initiation of antiretroviral therapy in children and adults with HIV.

Threats

• Recent tests, such as TST and IGRA, this test cannot distinguish between latent and active TB, nor can they determine if a person has been cured.
• TST needs many visits, and both TST/IGRA offer inconsistent outcomes based on BCG immunization.

Recent Developments in the Latent Tuberculosis Infection Detection Market

• In 2025, Prime Minister Modi announced a plan to eliminate tuberculosis in India by 2025. With more patients dying of TB in India than anywhere else in the world, this is a big step forward and hopefully will inspire other countries to take action.
• In November 2025, Serum Institute of India (SIIPL) Pvt. Ltd., part of Cyrus Poonawalla Group, in partnership with its UK subsidiary Serum Life Sciences Ltd, is pleased to announce that the Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom, has granted Marketing Authorisation for SIILTIBCY, a new tuberculosis (TB) skin test.

Segments Covered in the Report

By Brand

• QFT-Plus (QuantiFERON-TB Gold Plus)
• Others

By Test

• Tuberculin Skin Test (TST)
• Interferon Gamma Released Assay (IGRAa)

By Application

• Household Contacts with Pulmonary TB
• PLHIV
• Others

By End Use

• Diagnostic Laboratories
• Hospitals/Clinics
• Academic & Research Institutions

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA